High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia

Annals of Clinical Microbiology and Antimicrobials

Volumn 14, Issue 1, 2015, Pages

  Omrani, Ali S ^a   Alfahad, Wafa A ^b   Shoukri, Mohamed M ^a   Baadani, Abeer M ^b   Aldalbahi, Sultan ^b   Almitwazi, Ali A ^c   Albarrak, Ali M ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^c PRINCE SULTAN CARDIAC CENTER   (Saudi Arabia)

Author keywords

Acute kidney injury; CMS; Colistin; Colistin methanesulfonate; Nephrotoxicity; Saudi Arabia

Indexed keywords

COLISTIMETHATE; SERUM ALBUMIN; ANTIINFECTIVE AGENT; COLISTIN; MESYLIC ACID; MESYLIC ACID DERIVATIVE;

ADULT; ARTICLE; BIVARIATE ANALYSIS; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE INCREASE; FEMALE; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEPHROTOXICITY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK FACTOR; SAUDI ARABIA; TREATMENT DURATION; UNITED STATES; ACUTE KIDNEY INJURY; AGED; GRAM-NEGATIVE BACTERIAL INFECTIONS; MIDDLE AGED; PREGNANCY; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MESYLATES; MIDDLE AGED; PREGNANCY; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SAUDI ARABIA; YOUNG ADULT;

EID: 84924420301     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-015-0062-8     Document Type: Article

References (20)

1. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589-601.
2. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008;30:143-51. doi:10.1016/j.clinthera.2008.01.015.
3. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53:3430-6. doi:10.1128/AAC.01361-08.
4. Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol. 2011;11:464-9. doi:10.1016/j.coph.2011.07.004.
5. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honore PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1:14. doi:10.1186/2110-5820-1-14.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
7. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284-94. doi:10.1128/AAC.01733-10.
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
9. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204-12.
10. Balkan II, Dogan M, Durdu B, Batirel A, Hakyemez IN, Cetin B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis. 2014;46:678-85.
11. Sorli L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380. doi:10.1186/1471-2334-13-380.
12. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720-6. doi:10.1093/cid/cis286.
13. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother. 2012;56:2392-6. doi:10.1128/AAC.00028-12.
14. Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy. 2011;31:1257-64. doi: 10.1128/AAC.01707-09.
15. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53:879-84. doi: 10.1093/cid/cir611.
16. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect. 2011;62:187-90. doi:10.1016/j.jinf.2010.11.013.
17. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010;54:4503-5. doi:10.1128/AAC.01707-09.
18. Kwon JA, Lee JE, Huh W, Peck KR, Kim YG, Kim DJ, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents. 2010;35:473-7. doi:10.1016/j.ijantimicag.2009.12.002.
19. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48:1724-8. doi:10.1086/599225.
20. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents. 2009;34:434-8. doi:10.1016/j.ijantimicag.2009.06.028.